FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992123485> ?p ?o ?g. }

• W1992123485 endingPage "318" @default.
• W1992123485 startingPage "316" @default.
• W1992123485 abstract "To the Editor: Reduction of the cerebral metabolic rate of glucose is one of the most predominant abnormalities generally found in the Alzheimer brain, whereas the cerebral metabolic rate of oxygen is only slightly or not at all diminished at the beginning of this dementing disorder.1 This metabolic abnormality may induce functional disturbances preceding morphobiological changes. Recently, it has been claimed that a reduction in cerebral energy metabolism could be a primary event in the pathophysiological chain leading to excitotoxic neuronal death in neurodegenerative illnesses, with special emphasis for Alzheimer's disease.2 Cerebrospinal fluid (CSF) lactate and pyruvate levels provide a reliable measure of cerebral glucose metabolism. Lactate is mainly derived from glycolysis and removed by mitochondrial metabolism; therefore, increased CSF lactate concentration may be due to increased glycolysis, decreased respiration, or both, and elevation of both lactate and pyruvate has been considered as implying mitochondrial metabolic failure.3 We measured CSF levels of lactate, pyruvate and glucose in patients suffering from dementia of Alzheimer type (DAT) and in age- and sex-matched controls. The DAT group included 16 patients 68 ± 6.6 years old, with diagnosis of probable Alzheimer's disease according to the DSM III and the NINCDS-ADRDA criteria.4 The psychobehavioral assessment of demented patients was carried out by means of Mini-Mental State Exam (MMSE)5 for grading cognitive impairment and by means of GBS (Gottfries, Brane, and Steen) Rating Scale for Dementia.6 The control group consisted of 12 subjects 67 ± 4.2 years old, with no evidence of mental deterioration as shown by a MMSE score above 26, admitted to the orthopedic department for a suspected discus prolapse and subjected to lumbar puncture for diagnostic purpose (myelography). No subject had a history of psychiatric illness or alcohol abuse. Blood cell count, urinalysis, and blood chemistry tests using 12-factor automated chemical analysis (SMA-12) were within the normal range for all subjects. No subjects were taking drugs. In both controls and demented patients, lumbar punctures were performed between 8:00 and 10:00 AM, after informed consent, with the subject in sitting position after an overnight bedrest. Twelve mL of CSF were collected on ice, vortexed, divided in 1 mL aliquots, and immediately stored at −85°C until the analysis. Routine proteins analysis in serum and CSF and cytological investigations showed neither signs of acute inflammatory reaction nor blood brain barrier damage in any of the subjects studied. CSF glucose, lactate, and pyruvate concentrations were determined by means of quantitative enzymatic determination (SIGMA Diagnostics, St. Louis, MO). For lactate and pyruvate determinations, CSF samples were added 1:1 with 8% perchloric acid, then centrifuged at 12,000 rpm for 5 minutes and the supernatant taken for analysis. During the handling, samples were kept on ice. The DAT group showed significantly higher mean levels of lactate (P = 0.04) and pyruvate (P = 0.01) (Table 1), the latter being more than four times that of controls (Figure 1). Simple regression analysis showed no association between CSF lactate and pyruvate. CSF levels of lactate and pyruvate in controls and in Alzheimer's patients. These data suggest a defective utilization of pyruvate as substrate for mitochondrial oxidative phosphorylation in DAT. The oxidation of pyruvate to acetyl-coenzyme A, i.e., the step which connects glycolysis to the Krebs tricarboxylic acid cycle, is catalyzed by pyruvate dehydrogenase complex (PDHC). In Alzheimer's disease, PDHC activity is reduced, as postmortem studies7,8 have found, and evidence for an uncoupling of mitochondrial energy metabolism has also been found.9 CSF pyruvate levels above 5 mg/L could then represent a simple and inexpensive method in clinical practice to substantiate the diagnosis of Alzheimer's disease." @default.
• W1992123485 created "2016-06-24" @default.
• W1992123485 creator A5011919079 @default.
• W1992123485 creator A5012805399 @default.
• W1992123485 creator A5019846852 @default.
• W1992123485 creator A5050167610 @default.
• W1992123485 creator A5066190792 @default.
• W1992123485 creator A5078699758 @default.
• W1992123485 creator A5085986984 @default.
• W1992123485 creator A5090261825 @default.
• W1992123485 date "1995-03-01" @default.
• W1992123485 modified "2023-10-14" @default.
• W1992123485 title "INCREASED CSF PYRUVATE LEVELS AS A MARKER OF IMPAIRED ENERGY METABOLISM IN ALZHEIMER'S DISEASE" @default.
• W1992123485 cites W1847168837 @default.
• W1992123485 cites W1982682496 @default.
• W1992123485 cites W2019271502 @default.
• W1992123485 cites W2057791111 @default.
• W1992123485 cites W2062017626 @default.
• W1992123485 cites W2145213346 @default.
• W1992123485 cites W2156220037 @default.
• W1992123485 cites W2918081930 @default.
• W1992123485 doi "https://doi.org/10.1111/j.1532-5415.1995.tb07351.x" @default.
• W1992123485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7884130" @default.
• W1992123485 hasPublicationYear "1995" @default.
• W1992123485 type Work @default.
• W1992123485 sameAs 1992123485 @default.
• W1992123485 citedByCount "10" @default.
• W1992123485 countsByYear W19921234852012 @default.
• W1992123485 countsByYear W19921234852017 @default.
• W1992123485 countsByYear W19921234852023 @default.
• W1992123485 crossrefType "journal-article" @default.
• W1992123485 hasAuthorship W1992123485A5011919079 @default.
• W1992123485 hasAuthorship W1992123485A5012805399 @default.
• W1992123485 hasAuthorship W1992123485A5019846852 @default.
• W1992123485 hasAuthorship W1992123485A5050167610 @default.
• W1992123485 hasAuthorship W1992123485A5066190792 @default.
• W1992123485 hasAuthorship W1992123485A5078699758 @default.
• W1992123485 hasAuthorship W1992123485A5085986984 @default.
• W1992123485 hasAuthorship W1992123485A5090261825 @default.
• W1992123485 hasBestOaLocation W19921234851 @default.
• W1992123485 hasConcept C126322002 @default.
• W1992123485 hasConcept C134018914 @default.
• W1992123485 hasConcept C17093226 @default.
• W1992123485 hasConcept C20251656 @default.
• W1992123485 hasConcept C2779134260 @default.
• W1992123485 hasConcept C2779483572 @default.
• W1992123485 hasConcept C502032728 @default.
• W1992123485 hasConcept C62231903 @default.
• W1992123485 hasConcept C71924100 @default.
• W1992123485 hasConceptScore W1992123485C126322002 @default.
• W1992123485 hasConceptScore W1992123485C134018914 @default.
• W1992123485 hasConceptScore W1992123485C17093226 @default.
• W1992123485 hasConceptScore W1992123485C20251656 @default.
• W1992123485 hasConceptScore W1992123485C2779134260 @default.
• W1992123485 hasConceptScore W1992123485C2779483572 @default.
• W1992123485 hasConceptScore W1992123485C502032728 @default.
• W1992123485 hasConceptScore W1992123485C62231903 @default.
• W1992123485 hasConceptScore W1992123485C71924100 @default.
• W1992123485 hasIssue "3" @default.
• W1992123485 hasLocation W19921234851 @default.
• W1992123485 hasLocation W19921234852 @default.
• W1992123485 hasOpenAccess W1992123485 @default.
• W1992123485 hasPrimaryLocation W19921234851 @default.
• W1992123485 hasRelatedWork W2002888717 @default.
• W1992123485 hasRelatedWork W2003811568 @default.
• W1992123485 hasRelatedWork W2054690921 @default.
• W1992123485 hasRelatedWork W2063441939 @default.
• W1992123485 hasRelatedWork W2079012777 @default.
• W1992123485 hasRelatedWork W2082995727 @default.
• W1992123485 hasRelatedWork W2084171336 @default.
• W1992123485 hasRelatedWork W2099584401 @default.
• W1992123485 hasRelatedWork W2106490583 @default.
• W1992123485 hasRelatedWork W2171543951 @default.
• W1992123485 hasVolume "43" @default.
• W1992123485 isParatext "false" @default.
• W1992123485 isRetracted "false" @default.
• W1992123485 magId "1992123485" @default.
• W1992123485 workType "article" @default.